周五盘中，库拉肿瘤公司（Kura Oncology, Inc，股票代码：KURA）股价大幅下跌5.70%，主要原因是该公司公布的季度业绩远低于分析师预期。
根据公司最新发布的财报显示，截至6月30日的季度，库拉肿瘤公司调整后每股亏损为0.75美元，远超分析师平均预期的0.46美元亏损。此外，公司营收仅为1529万美元，同样大幅低于市场预期的3666万美元。这一疲软的业绩表现显然打击了投资者信心，导致股价应声下跌。
尽管本季度业绩表现不佳，但值得注意的是，分析师对该公司的长期前景仍保持乐观态度。目前，分析师对库拉肿瘤公司股票的平均评级维持在"买入"，其中13个评级为"强烈买入"或"买入"，2个评级为"持有"，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为28.00美元，较当前股价有显著上涨空间。这表明尽管短期内公司面临挑战，但市场对其长期发展潜力仍持积极看法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.